These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

96 related items for PubMed ID: 359210

  • 1. Successful immunosuppression of renal allograft recipients with alternate day steroid therapy.
    Burleson RL, Scruggs BF, Brennan A.
    Clin Nephrol; 1978 Sep; 10(3):87-9. PubMed ID: 359210
    [Abstract] [Full Text] [Related]

  • 2. Steroid withdrawal in kidney transplant recipients: is it a safe option?
    Sanfey H, Haussman G, Isaacs I, Ishitani M, Lobo P, McCullough C, Pruett T.
    Clin Transplant; 1997 Oct; 11(5 Pt 2):500-4. PubMed ID: 9361950
    [Abstract] [Full Text] [Related]

  • 3. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES, Bruce DS, Josephson M, Newell KA, Piper JB, Millis JM, Cronin D, Whitman G, Ruebe M, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [Abstract] [Full Text] [Related]

  • 4. Steroid treatment for routine immunosuppression in cadaver renal transplantation. A survey of hospitals.
    Kumar P, Leech SH, Gonzalez FM, Kodlin D.
    Proc Clin Dial Transplant Forum; 1996 Aug; 8():90-2. PubMed ID: 386327
    [Abstract] [Full Text] [Related]

  • 5. Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy.
    Curtis JJ, Galla JH, Kotchen TA, Lucas B, McRoberts JW, Luke RG.
    Clin Nephrol; 1976 Mar; 5(3):123-7. PubMed ID: 770034
    [Abstract] [Full Text] [Related]

  • 6. Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up).
    Roberti I, Reisman L, Lieberman KV, Burrows L.
    Clin Transplant; 1994 Aug; 8(4):405-8. PubMed ID: 7949548
    [Abstract] [Full Text] [Related]

  • 7. Alternate-day prednisone in the maintenance immunosuppressive therapy after orthotopic liver transplantation.
    Pedrosa MC, Rohrer RM, Kaplan MM.
    Clin Transplant; 1995 Aug; 9(4):322-5. PubMed ID: 7579741
    [Abstract] [Full Text] [Related]

  • 8. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Aug; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 9. Long-term outcome after switch from cyclosporine-based triple-drug immunosuppression to double therapy at three months.
    Aichberger C, Eberl T, Riedmann B, Pernthaler H, Ofner D, Königsrainer A, Margreiter R.
    Clin Transplant; 1996 Apr; 10(2):209-12. PubMed ID: 8664521
    [Abstract] [Full Text] [Related]

  • 10. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy.
    Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P, Astellas Corticosteroid Withdrawal Study Group.
    Ann Surg; 2008 Oct; 248(4):564-77. PubMed ID: 18936569
    [Abstract] [Full Text] [Related]

  • 11. Risk of steroid withdrawal in pediatric renal transplant patients with suspected steroid toxicity.
    Klaus G, Jeck N, Konrad M, Förster B, Soergel M.
    Clin Nephrol; 2001 Dec; 56(6):S37-42. PubMed ID: 11770812
    [Abstract] [Full Text] [Related]

  • 12. Influence of rejection on graft survival after renal transplantation.
    Lytton B, Finkelstein FO, Schiff M, Black HR.
    Trans Am Assoc Genitourin Surg; 1975 Dec; 67():99-102. PubMed ID: 788307
    [Abstract] [Full Text] [Related]

  • 13. Comparison of alternate day steroids and daily steroids in renal transplant recipients.
    Davisson NA, Westervelt FB, Bolton WK.
    Proc Clin Dial Transplant Forum; 1980 Dec; 10():150-4. PubMed ID: 7050977
    [Abstract] [Full Text] [Related]

  • 14. Selective corticosteroid and calcineurin-inhibitor withdrawal after pancreas-kidney transplantation utilizing thymoglobulin induction and sirolimus maintenance therapy.
    Knight RJ, Kerman RH, McKissick E, Lawless A, Podder H, Katz S, Van Buren CT, Kahan BD.
    Clin Transplant; 2008 Dec; 22(5):645-50. PubMed ID: 18657156
    [Abstract] [Full Text] [Related]

  • 15. Prednisone withdrawal in pediatric kidney transplant recipients on tacrolimus-based immunosuppression: four-year data.
    Hamiwka LA, Burns A, Bell L.
    Pediatr Transplant; 2006 May; 10(3):337-44. PubMed ID: 16677358
    [Abstract] [Full Text] [Related]

  • 16. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection.
    Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR.
    Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115
    [Abstract] [Full Text] [Related]

  • 17. Immunosuppression in live-related donor renal transplantation.
    Iman A, Rao M, Juneja R, Jacob CK.
    Natl Med J India; 2001 Aug; 14(2):75-80. PubMed ID: 11396322
    [Abstract] [Full Text] [Related]

  • 18. Steroid avoidance immunosuppression in low-risk kidney transplant recipients.
    Heilman RL, Mazur MJ, Reddy KS, Moss A, Post D, Mulligan D.
    Transplant Proc; 2005 May; 37(4):1785-8. PubMed ID: 15919466
    [Abstract] [Full Text] [Related]

  • 19. Randomized clinical trial of antithymocyte globulin in cadaver renal allograft recipients: importance of T cell monitoring.
    Cosimi AB, Wortis HH, Delmonico FL, Russell PS.
    Surgery; 1976 Aug; 80(2):155-63. PubMed ID: 781887
    [Abstract] [Full Text] [Related]

  • 20. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.